Amelioration of diabetic nephropathy in OLETF rats by prostaglandin If2 analog, beraprost sodium

American Journal of Nephrology

Volumn 30, Issue 1, 2009, Pages 1-11

  Watanabe, Maho ^a   Nakashima, Hitoshi ^a   Mochizuki, Shizue ^b   Abe, Yasuhiro ^a   Ishimura, Atsunori ^a   Ito, Kenji ^a   Fukushima, Takao ^a   Miyake, Katsuhisa ^a   Ogahara, Satoru ^a   Saito, Takao ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Beraprost sodium; Diabetic nephropathy; Otsuka long Evans tokushima fatty rat; Prostaglandin I2

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BERAPROST; CD68 ANTIGEN; CHOLESTEROL; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; LIPOPROTEIN; PLASMA PROTEIN; SERUM ALBUMIN; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG RESEARCH; GLOMERULOSCLEROSIS; GLOMERULUS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; KIDNEY; MACROPHAGE MIGRATION; MALE; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; EPOPROSTENOL; IMMUNOHISTOCHEMISTRY; KIDNEY; LIPIDS; LIVER; MALE; RATS; RATS, INBRED OLETF; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 58349114714     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000195722     Document Type: Article

References (59)

1. Wakai K, Nakai S, Kikuchi K, Iseki K, Miwa N, Masakane I, et al: Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant 2004;19:2044-2052.
2. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74 :1143-1155.
3. Makino H, Yamasaki Y, Haramoto T, Shika-ta K, Hironaka K, Ota Z, et al: Ultrastruc-tural changes of extracellular matrices in diabetic nephropathy revealed by high resolution scanning and immunoelectron microscopy. Lab Invest 1993;68:45-55.
4. Armstrong JM, Lattimer N, Moncada S, Vane JR: Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prosta-glandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol 1978;62:125-130.
5. Whittle BJ, Moncada S, Vane JR: Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins 1978;16:373-388.
6. Wang LN, Tang Z, Shou I, Fukui M, Tomino Y: Effects of the PGI2 analog beraprost sodium on glomerular prostanoid synthesis in rats with streptozotocin-induced diabetes. Nephron 1996;73:637-643.
7. Arima S, Ren Y, Juncos LA, Carretero OA, Ito S: Glomerular prostaglandins modulate vascular reactivity of the downstream efferent arterioles. Kidney Int 1994;45:650-658.
8. Yamashita T, Shikata K, Matsuda M, Okada S, Ogawa D, Sugimoto H, et al: Beraprost sodium, prostacyclin analogue, attenuates glo-merular hyperfiltration and glomerular macrophage infiltration by modulating ec-NOS expression in diabetic rats. Diabetes Res Clin Pract 2002;57:149-161.
9. 2 in incipient diabetic nephropathy. Nephron 2002;92:788-796.
10. Usui S, Nakamura M, Jitsukata K, Nara M, Hosaki S, Okazaki M: Assessment of be-tween-instrument variations in a HPLC method for serum lipoproteins and its trace-ability to reference methods for total cholesterol and HDL-cholesterol. Clin Chem 2000;46:63-72.
11. Okazaki M, Usui S, Hosaki S: Analysis of plasma lipoproteins by gel permeation chro-matography; in Rifai N, Wa rmick GR, Domi-niczak MH (eds): Handbook of Lipoprotein Testing. Washington, American Association of Clinical Chemistry Press, 2000, pp 647-669.
12. Mochizuki SM, Naganuma H, Narasaka T, Ueno Y, Sato H, Sasano H, Saito T: Significance of fat stains in serial sections from Epon-embedded tissue samples for electron microscopy in renal diseases. Clin Exp Nephrol 2001;4:240-245.
13. Lehr HA, Mankoff DA, Corwin D, Santeusa-nio G, Gown AM: Application of Photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997;45:1559-1565.
14. Lehr HA, van der Loos CM, Teeling P, Gown AM: Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem 1999;47:119-126.
15. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
16. Makita Z, Vlassara H, Rayfield E, Cart-w right K, Friedman E, Rodby R, et al: Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992;258:651-653.
17. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T: Spontaneous longterm hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-1428.
18. Okada M, Takemura T, Yanagida H, Yoshi-oka K: Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats. Kidney Int 2002;61:113 -124.
19. Makino H, Shikata K, Hironaka K, Kushiro M, Yamasaki Y, Sugimoto H, et al: Ultra-structure of nonenzymatically glycated mesa ng i a l matrix in diabetic neph ropathy. Kidney Int 1995;48:517-526.
20. Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, et al: Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997;46:1881-1887.
21. Raj DS, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: a ne-phrologist's perspective. Am J Kidney Dis 2000;35:365-380.
22. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790.
23. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
24. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al: Hyperglyce-mia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000;97:12222-12226.
25. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al: Benfotiamine blocks three major pathways of hyperglyce-mic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-299.
26. Banba N, Nakamura T, Matsumura M, Ku-roda H, Hattori Y, Kasai K: Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000;58:684-690.
27. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, et al: Cellular events in the evolution of experimental diabetic ne-phropathy. Kidney Int 1995;47:935-944.
28. Suzuki D, Miyazaki M, Naka R, Koji T, Ya-game M, Jinde K, et al: In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 1995;44:1233-1238.
29. Fur uta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, et al: The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993;21:480-485.
30. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al: Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002;277:20309-20315.
31. Wenzel UO, Abboud HE: Chemokines and renal disease. Am J Kidney Dis 1995;26:982-994.
32. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, et al: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide syn-thase. Circulation 2002;105:1656 -1662.
33. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, et al: NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005;288:F1144-F1152.
34. Onozato ML, Tojo A, Goto A, Fujita T, Wil-cox CS: Oxidative stress and nitric oxide syn-thase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002;61:186-194.
35. Veelken R, Hilgers KF, Hartner A, Haas A, Bohmer KP, Sterzel RB: Nitric oxide syn-thase isoforms and glomerular hyperfiltra-tion in early diabetic nephropathy. J Am Soc Nephrol 2000;11:71-79.
36. De Vriese AS, Stoenoiu MS, Elger M, Devuyst O, Vanholder R, Kriz W, et al: Diabetes-induced microvascular dysfunction in the hy-dronephrotic kidney: role of nitric oxide. Kidney Int 2001;60:202-210.
37. Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, et al: Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Di-abetologia 1998;41:1426 -1434.
38. Omer S, Shan J, Varma DR, Mulay S: Augmentation of diabetes-associated renal hy-perfiltration and nitric oxide production by pregnancy in rats. J Endocrinol 1999;161:15-23.
39. Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, et al: Nitric oxide synthesis and ox-idative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 2001;12:1630-1639.
40. Kihara M, Umemura S, Kadota T, Yabana M, Tamura K, Nyuui N, et al: The neuronal iso-form of constitutive nitric oxide synthase is up-regulated in the macula densa of angio-tensinogen gene-knockout mice. Lab Invest 1997;76:285-294.
41. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-2510.
42. Paliege A, Mizel D, Medina C, Pasumarthy A, Huang YG, Bachmann S, et al: Inhibition of nNOS expression in the macula densa by COX-2-derived prostaglandin E(2). Am J Physiol Renal Physiol 2004;287:F152-F159.
43. Bosse HM, Bohm R, Resch S, Bachmann S: Parallel regulation of constitutive NO syn-thase and renin at JGA of rat kidney under various stimuli. Am J Physiol 1995;269: F793-F805.
44. Singh I, Grams M, Wang WH, Yang T, Killen P, Smart A, et al: Coordinate regulation of renal expression of nitric oxide synthase, re-nin, and angiotensinogen mRNA by dietary salt. Am J Physiol 1996;270:F1027-F1037.
45. Tojo A, Kimoto M, Wilcox CS: Rena l expression of constitutive NOS and DDAH: separate effects of salt intake and angiotensin. Kidney Int 2000;58:2075-2083.
46. Matsumoto K, Morishita R, Tomita N, Moriguchi A, Yamasaki K, Aoki M, et al: Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue. J Endocrinol 2002;175:217-223.
47. Nakayama T: Prostacyclin analogues: prevention of cardiovascular diseases. Cardio-vasc Hematol Agents Med Chem 2006;4:351-359.
48. Kushiro M, Shikata K, Sugimoto H, Shikata Y, Miyatake N, Wada J, et al: Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat. Kidney Int 1998;53:1314-1320.
49. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al: Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005;16:703-711.
50. Schmitz PG, Kasiske BL, O'Donnell MP, Keane WF: Lipids and progressive renal injury. Semin Nephrol 1989;9:354-369.
51. Saito T: Abnormal lipid metabolism and renal disorders. Tohoku J Exp Med 1997;181:321-337.
52. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 1988;33:667-672.
53. Diamond JR, Karnovsky MJ: Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 1987;32:671-677.
54. Moorhead JF, Chan MK, El-Nahas M, Var-ghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;2:1309-1311.
55. Wilson PW, Kannel WB, Anderson KM: Lip-ids, glucose intolerance and vascular disease: the Framingham Study. Monogr Atheroscler 1985;13:1-11.
56. Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, et al: Apolipoprotein E genetic polymorphism, remnant lipopro-teins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002;40:243-251.
57. Hirano T: Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl 1999;71:S22-S24.
58. Yamagishi T, Saito Y, Nakamura T, Takeda S, Kanai H, Sumino H, et al: Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hy-pertens Res 2001;24:705-709.
59. Mishima K, Baba A, Matsuo M, Itoh Y, Oishi R: Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med 2006;40:1564-1577.